

Friday 24th March 2023

Delegate arrival & check-in

Breakfast Workshop 1

Breakfast Workshop 2

Breakfast Workshop 3

Opening of the Conference

Plenary 1 – Prevent, Diagnose and Support

Keynote Speaker, Harald Kittler

Consumer panel – focus on diagnosis / issues around new diagnosis of Melanoma

Morning Break

Session 1.1 - Melanoma: Burden, Control, Policy

- Incidence trends
- Costs from the diagnosis
- Costs: Primary Skin Check costs
- Methotrexate and melanoma
- Sun exposure guideline update

Panel Discussion

Session 1.2 - Diagnosis Melanoma, what now?

- Diagnostic biopsy impact on definitive treatment
 - Pathologist view
 - Surgeon's view
- Latest advances in surgery for melanoma
- Quality Performance Indicators in Melanoma Surgery
- SNB practical difficulties.

Session 1.3 - Basic Science 1

Lunch Break

Industry Session

Session 2.1 - Overdiagnosis: population perspectives, potential solutions.

- Screening and overdiagnosis
- Pathology – diagnostic drift
- Targeted screening program for melanoma

Panel Discussion

Session 2.2 - Surgery and Regional Treatment

- Local / regional treatment -regional surgery
- In transit Metastasis.
- Surgery for Stage IV disease in the era of active therapy
- Merkel Cell Carcinoma – Role of surgery

Session 2.3 - Basic Science 2

Afternoon Break

Session 3.1 - Epidemiology / Public Health
Free Papers

Session 3.2 - Oncology / surgery
Free Papers

Session 3.3 - Basic Science 3
Free Papers

Day 1 Closing

Saturday 25th March 2023

Delegate arrival & check-in

Breakfast Session
Industry Session

Breakfast Session
Dermoscopy workshop

Session 4.3
Genetic counselling for primary melanoma – workshop
Restricted to the first 30 participants who will register for a 2-hour workshop. Suitable for primary care / dermatologists and surgeons treating primary disease.

Session 4.1 - Locally advanced disease - multidisciplinary care

- Stage II adjuvant therapy
- Stage III adjuvant
- Desmoplastic-neoadjuvant /advanced
- In-transit disease

Cases / Discussion

Session 4.2 - The interchange between pathologists and clinicians

- Use and abuse of PRAME and SOX2 in the assessment of a melanocytic lesion
- When everything you thought you knew about Spitz goes BAM
- Reconceiving early detection of melanoma: the ACEMID cohort study
- Interventions to reduce over and under calling melanoma
- The effects of providing dermoscopic images to pathologists interpreting melanocytic lesion

Morning Break

Plenary 2: Neoadjuvant treatment

Keynote speaker, Alex van Akkoi
Keynote speaker, Georgina Long

Lunch Break

Industry Session

Session 5.1 - Issues in managing advanced Melanoma and melanoma at unusual sites

- Advanced disease-systemic therapy- PD/LAG3 role for prime time
- Advanced disease- is there ever a role for TT?
- Mucosal melanoma/acral melanoma- novel therapies and novel approaches
- Uveal melanoma - new and novel therapies

Case Discussion

Session 5.2 - Radiation Oncologist and Melanoma

- Role of RT for localized primary cutaneous melanoma and preinvasive disease
- Role of RT for resected and unresectable stage 3 cutaneous melanoma including ITD
- Role of SBRT in oligometastatic (oligo-persistent and -progressive) melanoma
- Sequencing of SRS and SRT with drugs for melanoma BM
- RT + IO interactions to improve melanoma outcomes

Session 5.3 - Overdiagnosis – clinical realities.

- The Rapid Rise in Cutaneous Melanoma Diagnosis
- Does overdiagnosis exist in the clinical practice?
- The role of imaging in the context of overdiagnosis
- The role of dermatopathology in Overdiagnosis
- Patient Personas and the Impact of Overdiagnosis
- Which lesions should we leave?

Panel Discussion

Afternoon Break

Session 6.1 - Advanced skin cancer

- Merkel Cell- NeoAdj and Adj-
- Translational research NMSCC
- Surgical role in NMSCC
- Neoadj/Adj cutSCC
- NMSCC in Transplant /immunosuppressed patients

Session 6.2 - Consumer Session

Session 6.3 - Clinico-pathologic Cases
A number of cases with expert panel including to allow discussion

Discussion / Cases

Conference Closing